Beam Therapeutics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −6.15%.
Did BEAM Beat Earnings? Q4 2025 Results
Beam Therapeutics delivered a striking earnings beat in Q4 2025, posting adjusted EPS of $2.33 against a consensus estimate of negative $1.01, a positive surprise of 330.69%, while revenue of $114.11 million cleared the $12.86 million consensus by 787.07% and rose 279.5% from the year-ago quarter. The headline driver was a $255.15 million gain on the sale of an equity method investment, which pushed the company to GAAP net income of $244.30 million compared to a net loss of $90.35 million a year earlier; absent that one-time item, Beam would have remained in the red. Revenue itself was propelled by Pfizer's opt-in to an exclusive worldwide license for a liver-targeted development candidate, concluding a four-year research collaboration. Looking ahead, Beam extended its cash runway into mid-2029, supported by a $1.25 billion year-end cash position and a new $500.00 million credit facility with Sixth Street, with key catalysts including a potential BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and updated BEAM-302 data expected by the close of Q1 2026.
- Gain on sale of equity method investment of $255.1 million drove Q4 net income
- License and collaboration revenue of $114.1 million in Q4 2025 versus $30.1 million in Q4 2024, reflecting Pfizer collaboration activities
- Strong cash position of $1.25 billion at year-end bolstered by collaboration payments and financing
“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development paths to approval across multiple high-value programs.”
Beam Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Beam expects its cash, cash equivalents, and marketable securities as of December 31, 2025 ($1.25 billion), combined with the anticipated $200 million minimum drawdown from the Sixth Street credit facility, to fund operations into mid-2029. Key 2026 milestones include: updated Phase 1/2 data and pivotal development path for BEAM-302 in AATD by end of Q1 2026; potential BLA submission for risto-cel in SCD as early as year-end 2026; IND filing for BEAM-304 in PKU in 2026; initial clinical data for BEAM-301 in GSDIa in 2026; and completion of BEAM-103 dosing in the first half of 2026.
BEAM YoY Financials
Figures from SEC filings and company reports. Not investment advice.